Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.

Johnson & Johnson failed to convince a federal judge that the US government acted unlawfully when it rejected the company’s ...

However, Friedrich declined to issue a declaration that rebate models are expressly prohibited under 340B law, in a partial win for drugmakers. Sanofi came out even more ahead.

And the 5-year growth (2018-2022) in 340B drug sales was 129.4%, more than three times the growth of non-340B drug sales, according to a 2024 report by IQVIA Market Access.

A HRSA analysis published in 2024 revealed that, in 2023, 340B covered entities purchased $66.3 billion in drugs under the program, making the 340B program the second-largest federal drug program ...

Sanofi (NASDAQ: SNY) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ET Company Participants Paul Hudson - Chief Executive Officer Francois-Xavier Roger - Chief Financial Officer ...

Novavax achieved its first $50 milestone payment from Sanofi. Sanofi sued the Department of Health and Human Services over payment terms for 340B hospitals. The Department of Justice issued a lawsuit ...

“If Sanofi implements its credit proposal without Secretarial approval, it will violate Section 340B (a) (1) of the Public Health Service Act (PHSA),” HRSA said, adding that Sanofi would be ...

Sanofi joins Johnson & Johnson, Eli Lilly and Bristol Myers Squibb, each of which has filed similar lawsuits in the U.S. District Court for the District of Columbia after rebuffed 340B rebate ...

The 340B statute allows sanctions for manufacturers that knowingly overcharge covered entities. HRSA has instructed Sanofi to halt the implementation of this credit model immediately and provide ...

Sanofi’s strategic focus on vaccines and immunology further supports its growth potential. The company is advancing its INBRX-101 program for AATD and is in active discussions with regulators to ...